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 Thrombosis of cerebral veins and sinus is a distinct cerebrovascular 
disorder, unlike arterial stroke, most often affects young adults and children. 
CVT may be difficult to diagnose clinically because of its various and non - 
specific manifestations and multiple associated conditions and etiologies. 
 During the past decade, increased awareness of the diagnosis, improved 
neuroimaging like 3D - MR imaging techniques, and more effective treatment 
has improved the prognosis. 
 Blood from the brain drains, through small cerebral veins into larger 
veins such as the vein of Galen. These bigger veins empty into dural sinuses 
which themselves are drained mostly by the internal jugular veins. The venous 
territories are less well defined than are arterial territories due the presence of 
extensive anastomoses between cortical veins. These allow the development of 
collateral circulation in the event of an occlusion. The main cerebral venous 
sinuses affected by CVT are the superior sagittal sinus and lateral sinus. 
 Pathophysiologically, there are important differences between arterial 
and venous thrombosis. CVT has been described as a continuing process in 
which the balance of prothrombotic and thrombolytic process is disturbed 
leading to progression of the venous thrombus with time. This slow growth of 
the thrombus and the good collateralisation of the venous vessels  probably 
explain the usually gradual onset of symptoms, frequently over weeks and 
months. Sudden onset, however has been described especially in post partum 
patients.  
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 The symptoms and signs associated with CVT are relatively nonspecific. 
Headache is the presenting symptom in 70 - 90% of cases. Focal deficits such 
as hemiparesis and hemisensory disturbances, seizures, impairment of level of 
consciousness and papilledema are other clinical presentations. Some patients 
can present with a syndrome resembling isolated intracranial hypertension, 
with headache, papilledema and visual disturbances.. The onset may be acute, 
subacute or insidious, most patients presenting with symptoms that evolved 
over days or weeks. 
 CVT can occur on a spontaneous basis or secondary to a hypercoaguable 
state, dehydration, infection,malignancy or dural sinus compression. 
predisposing factors can be identified in upto 80% of patients. Numerous 
conditions can cause or predispose to CVT and more than one cause can be 
found in a particular patient.  
 A principal distinction can be made between infective and non - 
infective causes. Amongst the non - infective causes, systemic conditions such 
as connective tissue disease, other  granulomatous or inflammatory disorders 
and malignancies are most common. In the middle East, Behcets disease may 
be responsible for upto 25% of cases. 
 In Young Women, CVT occurs more frequently during the puerperium 
than during pregnancy. Oral contraceptive and various coagulation disorders 
have been associated with increased risk of CVT. Hereditary prothrombotic 
conditions such as Factor V Leiden (Leading to increased resistance to 
activated protein C), deficiency of protein C and S, and antithrombin III as well 
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as prothrombin gene mutations may account for 10 - 15% of cases. The risk of 
a carrier of any of these prothrombotic conditions developing CVT in increased 
by the co-existence of other predisposing factors.  
 Investigations should focus in establishing the diagnosis and searching 
for underlying causes. CT, MRI, conventional angiography and more recently 
CT venography have been used to detect CVT. MRI conbined with MR 
venography has largely replaced invasive cerebral angiography and 
conventional CT. CT however remain the first imaging modality to be used  to 
exclude other conditions such as intra cerebral hemorrhage and abcess. MRV in 
conjunction with conventional MRI can accurately diagnose CVT and is 
reliable as the sole investigation for this condition. Recently CT venography 
has been shown to have sensitivity equal to MRV in visualising thrombosed 
sinus or cerebral veins. 
 Intravenous heparin should be the first - line treatment, even in the 
presence of hemorrhagic infarction, provided there are no general contra - 
indications to its use. If the patient deteriorates despite heparinastion or 
presents with moribund with coma, selective catheter guided thrombolysis may 
be an option, inspite of the increased hemorrhagic risk. This should be followed 
by 3 - 6 months of oral anti-coagulation. 
 Mortality ranks between 5.5% and 18% in recent series. More than 80% 




AIM OF THE STUDY 
 The aim of the present study are 
1. To study the clinical profile of patients with cerebral venous 
thrombosis. 
2. To study the neuro imaging findings, risk factors and possible 
etiology, clinical course and outcome in patients with cerebral 
venous thrombosis. 
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REVIEW OF LITERATURE 
BACKGROUND AND HISTORY 
 Cerebral vein and dural sinus thrombosis was first described in 1825 by 
Ribes60 in a post mortem report.  Since then many series have been published. 
However the true incidence of CVT is still unknown.  In most of the autopsy 
series, it was found very low.   
Thrombosis of cerebral veins & sinus in a distinct cerebrovascular 
disorder, that unlike arterial stroke affects young adults and children.  The 
symptoms and clinical course are highly variable.  The estimated incidence in 3 
- 4 case / million population. 
 During past decade increased awareness of diagnosis, improved 
neuroimaging techniques and more effective treatment has improved the 
prognosis. 
RELEVANT VENOUS ANATOMY 
Blood from brain is drained by cerebral veins that empty into dural 
sinuses, themselves mostly drained by the internal jugular vein. 
DURAL SINUSES 
Superior Sagittal Sinus 
 SSS lies in the attached border of the falx cerebri. It starts at the foramen 
caecum and runs backward towards the occipital protuberance, where it joins 
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with the straight sinus & lateral sinus to form the torcular herophili. The 
anterior part is narrow or sometimes absent, replaced by two cerebral veins that 
join behind the coronal suture. 
 The SSS receives superficial cerebral veins and drains major part of the 
cortex. It also receives diploic veins, themselves connected to scalp veins by 
emissary veins which explain some cases of SSS thrombosis after cutaneous 
infections.  
 The SSS and other sinuses play a major role in CSF circulation because 
they contain most of the arachnoid villi and granulations in which most of the 
CSF absorption takes place.  Thus there is a direct dependency of CSF pressure 
on intracranial venous pressure, accounting for the frequency on increased ICP 
with SSS or LS thrombosis. 
LATERAL SIUSES 
 The LS extend from the torcular herophili to the jugular bulbs and 
consists of two portions :- the transverse portion, which is attached to the 
tentorium & the sigmoid portion, which runs on the inner aspect of mastoid 
process and in thereby susceptive to infective thormbosis in patients with 
mastoiditis or otitis media. 
 This LS drain blood from cerebellum, brainstem and posterior part of 
cerebral hemisphere. They also receive some diploic veins and some small vein 
from middle ear, yet another possible source of septic thrombosis. Numerous 
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LS anatomic variations may be misinterpreted as sinus occlusion in 
angiography.  In particular, the right LS which often a direct continuation of 
SSS is frequently larger than the left which receives most of the blood from the 
straight sinus. In Hackers 43 study, the transverse portions were not visualised 
on ipsilateral carotid angiogram in 14% cases on left side and in 3.3% on right 
side whereas sigmoid portions which may be directly injected via cerebral 
veins, failed to fill 4% of cases in the left side and were always demostrated on 
the right. An isolated lack filling of left transverse sinus is thus more suggestive 
of hypoplasia than thrombosis. 
CAVERNOUS SINUS 
 Cavernous sinus consists of trabeculated cavities formed by separation 
of layers of the dura & located on each side of the sella turcica, superolateral to 
the sphenoid air sinus.  The oculomotor, trochlear cranial nerve, along with the 
ophthalmic and maxillary branches of the trigeminal nerve, course along the 
lateral wall of the cavernous sinuses, whereas the abducens nerve and carotid 
artery with its surrounding sympathetic fibres plexus are located within the 
centre of the sinus. 
Cavernous sinuses drain the blood from the orbits through the opthalmic 
veins & from the anterior part of the base of the brain by sphenoparietal sinus 
and middle cerebral veins. They empty into both the superior and inferior 
petrosal sinus and ultimately into the internal jugular veins. In contrast to other 
varieties of sinus thrombosis, infection is still the leading cause of thrombosis. 
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CEREBRAL VEINS 
 The three groups of veins that drain the blood supply from the brain are 
superficial cerebral (or cortical), the deep cerebral veins of the posterior fossa. 
SUPERIOR CEREBRAL VEINS 
 Some of the cortical veins, the frontal, parietal and occipital cerebral 
veins drain the cortex ascendingly into the SSS, whereas the middle cerebral 
vein drain descendingly into cavernous sinus. These veins are linked by  
Trolard great anastamotic vein which connects SSS to middle cerebral vein. 
The middle cerebral vein is connected to CS by Labbe's vein. 
 These cortical veins have thin walls, no muscle fibres and no valves, 
permitting both dilatation and reversal of the direction of blood flow when the 
sinus in which they drain is occluded. They are linked by numerous 
anastomoses allowing development of a collateral circulation, which probably 
explains the good prognosis of same CVT. The number and location of cortical 
are inconstant. This anatomical variability, together with the possibility of flow 
reversal and development of collateral circulation, accounts for the absence of 
well delineated venous territories and consequently of well defined clinical 
syndromes of cortical vein thrombosis. 
DEEP CEREBRAL VEINS 
 Blood from deep white matter of cerebral hemispheres & from the basal 
ganglia is drained by the internal cerebral and basal veins that join to form the 
great vein of Galen which drains into straight sinus.  Deep system is constant 
and always visualised at angiography, so that its thrombosis is easily 
recognised. 
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VEINS OF THE POSTERIOR FOSSA 
 They are divided into three groups: superior veins draining into the 
Galenic system, anterior veins drains into the petrosal sinus and posterior veins 
draining into the torcular & neighbouring SS and LS. 
PATHOGENESIS 
 To understand the symptomss and signs of sinus thrombosis two 
different mechanisms should be distinguished. 
1. Thrombosis of cerebral vein - with local effects caused by venous 
obstruction. 
2.  Thrombosis of the major sinus - which cause increased 
intracranial pressure. 
I Occlusion of the cerebral vein causes localised edema of the brain 
and venous infarction.  The latter can merge and become large hematomas 
which have characteristic appearance on CT scan.  Two different kinds of 
cerebral edema can develop. 
*Cytotoxic edema caused by ischemia which damages energy 
dependent cellular pumps leading to cellular swelling. 
*Vasogenic edema caused by disruption in thee blood brain barrieer 
and leakage of blood plasma into interstitial space. Vasogenic edema in 
reversible if the condition is treated successfully. 
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II. Thrombosis of major sinus : The second mechanism is 
development of intracranial hypertension as a result of occlusion of the major 
venous sinus. Thrombosis of sinus leads to increased venous pressure, impaired 
absorption of CSF through subarachnoid villi and consequently increased 
intracranial pressure. 
 The obstruction to the drainage of CSF is located at the end of the 
transport pathway and no pressure gradient develops between subarachnoid 
spaces at the surface of the brain and ventricles.  Hence ventricles do not dilate 
and  hydrocephalus does not normally complicate sinus thrombosis.  About 
1/5th of patient with sinus thrombosis have intracranial hypertension only 
without signs of cortical venous thrombosis. 
The international study on cerebral veins & dural venous thrombosis 
(ISCVT)38, observed the following frequencies of thrombosis in various sinus: 
  Superior sagittal sinus    - 62% 
  Transverse sinus      - 86% 
  Vein of Galen & internal cerebral vein  - 11% 
  Jugular veins      - 12% 
  Cortical veins     - 17% 
EPIDEMIOLOGY 
 The exact incidence of CVT, in still under debate because of scarcity of 
scientifically planned epidemiological studies in the available literature.  
Hospital data has been used to determine its prevalence in the community. 
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 Kalbag & Woolf et al46 indicated that CVT was the principal cause of 
death in only 21.7 persons/year in England & Wales between 1952 & 1961. 
 Towbin et al72 found in 9% of 182 consecutive autopsies insists that 
primary CVT in adults in still under recognised disease. 
 On the other hand in studies Nagaraja et al52, Chopra et al22 & 
Srinivasan et al66, aseptic CVT occuring in pregnancy and puerperium has been 
reported very frequently from the Indian subcontinent and CVTconstitutes 10 -
15% of stroke in the young and was commonest cause of stroke in 
premenopausal women. 
 Srinivasan et al60 encountered 50 cases of severe CVT amongst 1000 
deliveries performed per year.  It has been estimated the prevalence rate in 
developing countries in approximately 10 times more than the developed 
countries. 
 The more recent publication of large scale series, suggest that over the 
past 5 to 10 years CVT has been diagnosed more frequently due to greater 
awareness and availability of better non-invasive diagnostic techniques.  CVT 
is slightly more common in women particularly in the age group of 20 to 35 
due to pregnancy, puerperium & OCP use.  Mean age in most large studies was 
between 37 & 38 years though all ages can be affected. 
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CAUSES AND RISK FACTORS 
 Predisposing factors can be identified in upto 80% of patients (Bousser 
et al)9.  Numerous conditions can cause or predispose to CVT and often more 
than one cause will be found in an individual.  A prinicipal distinction can be 
made between infection and non-infectious causes. 
 In Bousser et al.,9 infective cases have declined and were responsible 
only for 8% of causes.  Cavernous sinus thrombosis remains the most common 
form of septic thrombosis usually following staphylococcal infections of 
middle third of the face.  Other infections include sphenoid or ethmoid 
sinusitis, dental abscess and less often otitis media. 
 Among the non-infective causes, CVT occurs frequently during 
puerperium than in late pregnancy and remains very common in developing 
countries whereas in the developed countries the role of OCP is more 
important. 
 De Bruijn et al.,27,29 found in age adjusted odds ratio of 13 for OCP  use 
and risk of CVT. Hereditary prothombotic conditions such as Factor V Leiden 
(leading to increased resistance to activated protein C), deficiency of protein C, 
protein S and antithrombin deficiency  as well as prothrombin gene mutations 
account for 10 - 15% of case of CVT.  The detection of congenital 
thrombophilia should be systematic in CVT since it potentiates the risk of 
venous thrombosis associated with other condition including OCP or 
puerperium. 
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 Other causes include connective tissue disorders, granulomatous & 
malignancies.  Daif et al.,25 in study of 40 cases from Saudi Arabia found that 
in the Middle East, Behcet's disease may be responsible in 25% of cases. 
 The etiology remains unknown in 20 - 35% of cases. Finding etiology 
for CVT necessitates an extensive initial working and when no cause in found,  
a long term follow up with repeated investigations. In some cases initially 
interpreted as idiopathic, a general disease can be discovered some months 
later. 
CAUSES & PREDISPOSING CONDITIONS68 
I. Infectious causes 
 LOCAL 
  Otitis, mastoiditis and sinusitis 
  Meningitis, intracranial abscess 
  Direct septic trauma 
 GENERAL 
  Systemic infectious disease (Bacterial, viral, fungal and parasitic) 
II. NON-INFECTIOUS CAUSES 
 GENETIC PROTHROMBOTIC CONDITIONS 
  Antithrombin III deficiency 
  Protein C & S deficiency 
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  Factor V Leiden mutation 
  Prothrombin mutation (20210) 
  Homocysteinemia 
 ACQUIRED PROTHROMBOTIC STATES 
  Nephrotic syndrome 
  Antiphospholipid antibodies 
  Homocysteinemia 
  Pregnancy 
  Puerperium 
 INFLAMMATORY DISEASES 
  SLE 
  Behcet's disease 
  Inflammatory bowel disease 
  Wegener's granulomatosis 
  Sarcoidosis 
 HEMATOLOGIC CONDITIONS 
  Polycythemia (primary & secondary) 
  Thrombocythemia 
  Leukemia 
  Anemia 
 DRUGS 
  OCP 
  Asparaginase 
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 MECHANICAL CAUSES 
  Head injury 
  Injury to sinus or jugular vein, jugular vein catheterization 
  Neurosurgical procedures 
  Lumbar puncture 
 MISCELLANOUS 
  Dehydration especially children 
  Malignancies 
CLINICAL MANIFESTATIONS 
 CVT presents with a wide spectrum of symptoms and signs: 
* In Bousser et al9 series, headache is the presenting symptom in 70 
- 90% of cases. 
- the earliest symptom in two third of cases. 
- it has no specific features. 
- its mostly diffuse, progressive and permanent but it can 
misleading, minicking migraine or headache of SAH. 
* Focal deficits such as hemiparesis & hemisensory disturbances, 
seizures, impairment of consciousness and papilledema occurs in 
one third to three quarters of cases.  Other signs such as 
cerebellar incoordination or psychiatric disturbances can occur. 
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* Seizures occur in 40% of cases, a far higher percentage than 
arterial stroke. Seizures are limited and focal in 50% of these 
patients but may generalise to life threatening status epilepticus. 
 Thrombosis of deep venous system - the straight sinus & its branches - 
causes centrally located often bilateral thalamic lesions with behavioural 
symptoms such as delirium, amnesia and mutism which may be the only 
manifestation of sinus thrombosis. 
 Causes of coma in CVT include brainstem compression due to the 
infarct/hemorrhage, seizures and involvement of thalamus. Patients with 
increased intracranial tension have headache but no neurologic symptoms with 
exception of diplopia due to involvement of sixth nerve when the intracranial 
pressure is high. 
 The mode of onset of symptoms is highly variable. In Bousser MG12 et 
al series of 135 patients it was acute (<48hrs) in 37 patients (27%), subacute 
(>48 hrs to <30 days) in 67 patients (50%) and chronic (>30 days in 31 patients 
(23%). 
DIAGNOSIS 
 Although the clinical presentation is highly variable, diagnosis of CVT 
should be considered in young and middle aged patients with  
i) Recent unusual headache or stroke like symptoms in the absence 
of usual vascular risk factors. 
ii) In patients with intracranial hypertension and  
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iii) In patients with CT evidence of hemorrhagic infarcts especially if 
the infarcts are multiple and not confined to arterial vascular 
territories. 
The average delay from the on set of symptoms to diagnosis is seven 
days. 
INVESTIGATIONS 
 CVT is an uncommon condition and hence unless this condition is 
suspected prior to embarking on investigations the diagnosis is likely to be 
missed.  Therefore, it is reasonable to entertain this diagnostic possibility if the 
circumstances are conducive to development of CVT. 
1. COMPUTED TOMOGRAPHY 
 CT scan with and without contrast injection is the first neuroimaging 
examination carried out in patients with headache, focal deficits or seizures 
particularly on an emergency basis. CT scan is extremely useful to rule out 
many of the conditions that CVT mimics. It can occassionally detect the lesions 
that can themselves cause CVT such meningiomas, abscess, sinusitis & 
mastoiditis. 
 CT findings can be divided into direct and indirect signs. 
DIRECT SIGNS OF CVT 
 a. Cord sign 
- visible on unenhanced CT scan represents the spontaneous 
visualisation of thrombosed cortical veins. 
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 According to Bousser et al12, it is extremely rare in his series ( 1 in 116 
cases of his series). It is also seen in internal cerebral vein and vein of Galen 
thrombosis. 
 b. Dense triangle sign 
- Reflects spontaneous SSS opacification by freshly 
coagulated blood. 
 It was present in less than 2% of case of Bousser et al12. 
 c. Empty delta sign 
-  was described by Buonanno et al15, appears after contrast 
injection & reflects the opacification of collateral veins in 
the SSS contrasting with non-injection of clot inside the 
sinus. 
 It is the most frequent direct sign approximately 35% of published cases. 
Indirect signs of CVT 
- Intense contrast enhancement of falx and tentorium. Tentorial 
enhancement is usually thought due to straight sinus thrombosis. 
 -  Small ventricular system 
 -  Reduction of sulcal pattern due to cerebral edema 
- White matter hypodensity without contrast enhancement 
suggestive of cerebral edema (present upto 75% of cases in study 
by Ford et al.,41) 
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- Hemorrhagic, venous infarcts in 10 - 50 % of the cases.  In rare 
instances there is associated subarachnoid hemorrhage or 
subdural hematoma. 
 - Non hemorrhagic venous infarcts are also frequent. 
 The place of CT scan in the diagnostic strategy of CVT in mainly to rule 
out other conditions such as arterial stroke, abscess, tumors and SAH on 
emergency basis.  In 10 - 20% cases, CT is normal in patient proven CVT. In a 
minority of cases it will show direct pathognomic signs of CVT but more 
frequently only indirect signs are present and MRI or angiographic information 
should be obtained. 
 Recently CT venography has been shown to have sensitivity equal to 
MRV in visualising thrombosed sinus or cerebral veins. 
2. MAGNETIC RESONANCE IMAGING 
 MRI offers major advantages for the evaluation of possible CVT - 
sensitivity to blood flow, ability to visualise the thrombus itself and non 
invasiveness.  A variety of MR findings have been described, mainly relating to 
the evaluation of thrombosis, which evolve over time. 
1. In acute phase - absence of normal venous flow void in T1 & T2 
weighted images. Thrombus itself appears isotense in T1 & 
hypointense in T2 weighted images. 
2. During 5 - 15 days, absence of flow void persists but the 
thrombus becomes hyperintensive initially the thrombus becomes 
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hyperintense intially in T1 & then on T2 weighted images.  In 
large vessels, these changes start in the periphery and proceed 
towards the centre.  They represent the aging of the thrombus 
with biochemical conversion of oxyhemoglobin to 
methhemoglobin. 
This intermediate pattern (increased signal on T1 & T2 weighted 
images) is diagnostic of CVT and is by far the most frequent. 
 3.  Late changes ( approximately 2 to 4 weeks after onset) 
Can reveal the beginning of vascular recanalisation with resumption of 
flow void in the previously thrombosed vessels. 
 However at 6 months, more than two third of cases still have some 
heterogenous localised signal abnormalities which can persist for years and 
should not be mistaken for recurrent acute CVT.  In some cases, however, 
interpretation of MRI images is not easy because of false-negative and false-
positive images. 
 The combination of non-contrast MRI plus MRA is now-a-days the best 
method for the diagnosis & follow-up of CVT.  It should be performed as first 
investigation in case of high clinical suspicion.  Its use is limited in certain 
situations such as deeply comatose subjects requiring artificial ventilation. 
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OTHER NEUROLOGIC INVESTIGATIONS 
3. ANGIOGRAPHY 
 IA angiography ± DSA provides high definition images but is associated 
with small (<5%) risk of neurological complications.  Filling deficits within 
dural sinus or their complete occlusion demonstrated an delayed venous phase 
projections.  It can also demonstrate appearance of deep and superficial cortical 
collateral veins ( cork-screw veins). 
4. LUMBAR PUNCTURE 
 - To exclude other pathologies such as meningitis and SAH. 
-  CSF in CVT may be normally or there may be an increase in 
protein, white cells, red cells alone or in combination. 
-  Measurement of CSF pressure may be useful in establishing a 
baseline & also as a therapeutic measure if vision is threatened. 
5. GENERAL INVESTIGATION 
            After CVT has been established, investigations should be directed 
toward demonstrating the underlying etiology. Because of multiplicity of 
etiologies, this is a long & difficult task whenever the cause is not clinically 
evident. Fever, increased ESR or PMN  points to infective, inflammatory or 
malignant cause. 
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 Investigations for hereditary thromboophilic conditions like factor V 
Leiden mutation, protein C and protein S, deficiency, antithrombin deficiency, 
homocysteinemia, should be done systemically looked for in patients with 
CVT, whether or not other potential causes are present, because the risk of 
CVT in patients  carrying any of these prothrombotic conditions, is increased 
by co-existence of other predisposing factors. 
 Investigations for connective tissue disorders like ANA, APLA, Behcet's 
may be done in suspected cases. 
TREATMENT 
 General Measures 
 The combination of acutely increased intracranial pressure & large 
venous infarcts is dangerous and patient die within hours from cerebral 
herniation.  The priority of treatment in the acute phase is to stabilise the 
patients condition and to prevent or reverse cerebral herniation. 
 This may require the administration of IV mannitol, surgical removal of 
the hemorrhagic infarct or decompressive hemicraniotomy.  It is not known 
whether administration of corticosteroids in the acute phase improves outcome.  
Possible causes of sinus thrombosis such as infections, connective tissue 
disorders and malignancies should be searched for and treated. Antibiotic 
treatment very important in CVT due to infectious causes. 
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 Symptomatic treatment, like anticonvulsants are very important in 
patients who present with seizure. The question of duration of treatment with 
anticonvulsants remain open. In Bousser et al.,12 anticonvulsants were 
progressively discontinued 1 year after CVT in patients with normal EEG and 
no recurrent seizures. 
Anticoagulation 
 The most obvious treatment option in anticoagulation with heparin to 
arrest the thrombotic process & to prevent pulmonary emboli which may 
complicate sinus thrombosis.  However, anticoagulation treatment has raised 
much controversy because of the tendency of venous infarcts to become 
hemorrhagic and about 40% of all patients with sinus thrombosis have 
hemorrhagic infarct even before anticoagulation is started. 
 A study by Einhaupl et al.,36 showed significant benefit with heparin 
even patients who had hemorrhagic infarcts.  Diaz et al.,33 reviewed 203 CVT 
cases reported between 1942 & 1990 and compared the outcome of patients 
treated and not treated (149) with heparin. 91% survived in the first group 
compared with 36% in the second group. 
 Nagaraja et al.,54 compared the effect of IV un-fractionated heparin with 
that of placebo in 57 women from India who had puerperal sinus thrombosis 
which showed a non-significant benefit of anticoagulant treatment as compared 
with placebo. There is thus good evidence that the benefit / risk ratio of heparin 
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is favourable in patients with CVT, but there are still disagreements on the best 
indications. 
 Most neurologist now start treatment with heparin as soon as this 
diagnosis of CVT in confirmed even in the presence of hemorrhagic infarcts 
unless contra-indication exists for their general use.  There are no studies that 
compared the effect of un-fractionated heparin in treatment with sinus 
thrombosis.  There is no fixed duration for heparin treatment but empirically it 
is prolonged until the patient improves or atleast stabilises. 
 It is then replaced with oral anticoagulants to obtain an INR between 2.5 
and 3.5. Usually vitamin K antagonists are given are six months after 1st 
episode of sinus thrombosis.  But prolonged treatment is warranted whenever 
prothombotic situation exists such as malignancy, inflammatory disease 
(Behcet's disease and SLE), inherited thrombophilia or history of recurrent 
venous thromboses. 
Thrombolytics 
 Anticoagulants are widely used as first line therapy, their rationale being 
to avoid thrombus extension and favour spontaneous thrombus dissolution.  
Thrombolysis is considered when a rapid recanalisation is sought especially in 




SHORT TERM OUTCOME: 
Mortality 
 There are three main causes of death in CVT - the brain lesion itself, 
particularly when massive hemorrhagic infarct is present, intercurrent 
complications such as sepsis, uncontrolled seizures and pulmonary embolism.  
In the series by Bousser MG et al.,9 Einhaupl et al.,36 DeBruijn et al.,30 the 
mortality ranks between 5.5% and 18%. 
 Factors classically considered to suggest a bad prognosis are the rate of: 
 - rapid evolution of thrombus. 
 - age of the patient ( with high mortality in infants & aged). 
 - infectious etiology. 
 - focal symptoms and coma. 
 - presence of hemorrhagic infarct. 
 - involvement of deep cerebral and cerebellar vein thrombosis. 
DeBruijn et al30., a study of prospective series of 59 patients identified 
that following factors related to poor outcome after 12 weeks, 
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* Papilledema,  
* Altered sensorium,  
* Coma,  
* Age older than 33 years, 
* Diagnostic delay < = 10 days,  
* Intracerebral hemorrhage,  
* Involvement of straight sinus. 
 Isolated intracranial hypertension and delta sign on CT were associated 
with good outcome.  
FUNCTIONAL RECOVERY AND LONG TERM OUTCOME 
 It has long been recognised that if survival occurs in CVT, the prognosis 
for recovery of function is much better than in arterial thrombosis. A minority 
(15 to 20%) of patients are left with disabling sequelae such as focal deficits 
seizures, optic atrophy. In a study of 79 patients by Stolz E et al.,70 most 
frequent complications on long term follow-up was epilepsy and recurrent 
venous thrombosis. 
 According to Preter et al.,58 on follow-up of 77 patients residual epilepsy 
was reported in 10 - 30% of the patients and recurrence was seen in 11.7% of 
patients. 
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MATERIALS AND METHODS 
PATIENTS AND METHODS 
 The subjects for the present study comprised of patients admitted in 
Government General Hospital in Medical and Neurology Wards, Chennai, 
during the period of September 2003 and January 2006. (About 47 patients of 
age between 15 - 70 years were studied). 
INCLUSION CRITERIA 
 The subjects were diagnosed to have CVT and included in the study 
when an appropriate clinical picture of the patient was supported by one or 
more of the following. 
1. CT Scan - showing unequivocal direct or indirect evidence of 
cerebral  venous thrombosis. 
2. MRI showing evidence of cerebral venous thrombosis. 
a. Partial can complete absence of filling of one or more 
dural  sinus. 
b. Visualisation of thrombus +  
  c. Parenchymal lesions suggestion of CVT. 
 3. Age of the patient >14 years. 
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 A total of 47 patients (24 men and 23 women) fulfilling the above 
criteria were studied. 
* A detailed clinical history was taken with special emphasis on the 
suspected precipitating or predisposing factors dehydration, 
fever, sepsis, anemia, parity, underlying medical illness, obstetric 
history, joint pains, oral / genital ulcers, abortions, oral 
contraception. 
 * Detailed examination of the patients was carried out including : 
a. General physical examination - any evidence of anemia, 
dehydration, sepsis, deep vein thrombosis of leg or 
arthritis was noted. 
b. Cardiovascular, respiratory and per abdominal 
examination was carried out to look for any evidence of 
systemic involvement. 
c. A detailed neurological examination was done which 
included (i) assessment of level of sensorium (ii) any 
evidence of raised intracranial tension and iii) any focal 
deficits or bilateral neurological signs and iv) any 
evidence of meningeal limitation. 
* All the patients were investigated with hemogram, ESR, Total 
and differenital leucocyte counts, platelet count, blood sugar, 
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Blood urea, serum creatinine, lipid profile, bleeding time, clotting 
time, prothrombin time, urine analysis, chest x-ray. 
 All the patients underwent CT scan of head plain and with contrast 
enhancement. 
 Also all the patient underwent MRI imaging of brain with MR 
angiogram (venogram). 
 CSF analysis was done any in 3 patients with meningeal signs.. 
 Other ancillary investigations, protein C, protein S APLA, ANA, anti - 
thrombim III were performed only in few patients with high clinical suspician. 
 The results were analysed.  
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OBSERVATIONS AND RESULTS 
I. AGE AND SEX DISTRIBUTION 
Table - 1A : Age Distribution 
Age No. of Patients Percentage 
15 - 20 2 4% 
21 - 30 26 55% 
31 - 40 15 31% 
41 - 50 1 2% 
51 - 60 2 4% 
61 - 70 1 2% 
 
 Mean age of the total cohort - 28.5 years (Range 15 to 70 years). 
Table I B : Sex Distribution 
Sex No. of Patients Percentage 
Males 24 51% 
Females 23 49% 
 
 There were 24 men (51%) and 23 women (49%) in the study. 
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II. AGE DISTRIBUTION BETWEEN PUERPERAL AND NON - 
PUERPERNAL GROUPS. 
 No. of Patients Percentage Mean Age 
Puerperal 14 29.7% 25.1 years 
Non Puerperal 33 60.8% 31.7 years 
 
 Of the 47 patients 14 patients (29.7%) were puerperal. Most of the 
patients (60.8%) were cases of non - puerperal CVT. 
 Mean age of puerperal CVT - 25.1 years. 
 Mean age of non - puerperal CVT - 31.7 years 
 Patients with puerperal CVT were of relatively younger age. 
III. MODE OF ONSET IN TOTAL COHORT AND PUERPERAL 
CVT PATIENTS. 
 Table III shows mode of onset of the symptoms. Those who presented 
within 48 hours were considered to have acute onset; with onset longer than 48 
hrs but less than 1 month as sub - acute, and with onset more than one month as 
Chronic (Bousser et al.,9). 
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TABLE IIIA - MODE OF ONSET IN TOTAL COHORTS 
 No. of Patients(47) Percentage 
Acute 11 23.4% 
Subacute 33 70.2% 
Chronic 3 64% 
 
 Most of the patients had a sub-acute presentation. 
 11 (23.4%) had acute, 33 (70.2%) had sub-acute and 3(6.4%) had 
chronic onset. 
TABLE IIIB - MODE OF ONSET IN PUERPERAL AND NON 
PUERPERAL CVT PATIENTS 
 
Puerperal                              
(n = 14) 
Non Puerperal          
(n = 33) 
Acute 8 (57%) 3(9.1%) 
Subacute 6 (43%) 27(81.8%) 
Chronic - 3(9.1%) 
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 Most of the puerperal CVT patients had acute onset of presentation. 
8(57%) had acute onset and 6(43%) had subacute onset. No patients with 
puerperal CVT had chronic onset of symptoms. 
 Most of the non - puerperal CVT had subacute onset of presentation. 
3(9.1%) had acute onset, 27(81.8%) had sub-acute onset and 3(9.1%) had 
chronic onset. 
TABLE IVA - CLINICAL FEATURES 
 
 No. of Patients 
(n=47) 
Percentage 
Symptoms   
Headache 40 85% 
Seizures 19 40.4% 
Alteration on level of consciousness 22 46.8% 
Signs   
Focal Deficits 26 55.3% 
  i. Sensory 1 2% 
  ii. Motor    
  * Hemiparesis / Hemiplegia 15 31.9% 
 * Monoparesis / Monoplegia 5 10.6% 
 *  Paraplegia 1 2% 
 * Multiple cranial nerve deficits 4 8.5% 
Bilateral papilledema 37 78.7% 
Meningeal Irritation signs 3 6.3% 
Isolated ICT 13 27.6% 
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 Headache was the most common presenting system. It was seen in 
40(85.1%) cases. 
Seizures were another common symptom at presentation. 19 patients 
(40.4%) of all cases had seizures.  
Table IVB give the  distribution of type of seizures in each group.  
TABLE - IVB : TYPE OF SEIZURES 
 No. of Patients 
(n=19) 
Percentage 
Focal 2 10.5% 
Focal with secondary generalisation 1 5.2% 
GTCS 13 68.4% 
Status epilepticus 3 15.7% 
 
 68.4% of the cases with seizures were generalised term clonic seizures. 
While 10.5% had focal seizures, 5.2% had focal seizures with secondary 
generalisation. 15.7% presented with status eplilepticus. 
TABLE - IVC : LEVEL OF CONSIOUSNESS AT PRESENTATION 
 No. of Patients 
(n=47) 
Percentage 
Consious 25 54.2% 
Altered level of consiousness 22 46.8% 
Drowsy 10 21.2% 
Stupor 8 17% 
Coma 4 8.5% 
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 22 patients (46.8%) had alteration in consiouness level at presentation. 4 
patients were comatose at presentation.  
 At presentation bilateral papilledema as present in 37 patients (78.7%). 
 13 patients (27.6%) presented with features isolated intracranial 
hypertension. 
 Focal deficits were present in 26 (55.3%). Hemiparesis was the common 
focal deficit in 15(57.6). 5(19.2%) had monoparesis (faciobrachial 
monoparesis), 1(3%) had paraplegia, 4(15.3%) had multiple cranial nerve 
deficits, 1(2%) had sensory disturbance. 
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TABLE V -  CT SCAN FIDNINGS 
 No. of Patients 
(n=47) 
Percentage 
Normal 10 21.2% 
Non - hemorrhagic infarct 9 19.1% 
Hemorrhagic infarcts 17 36.1% 
Intrancerebal hematoma - - 
Sub-arachnoid hemorrhage 3 6.2% 
Sub-dural hematoma 1 2% 
Direct Signs   
Cord Sign 4 8.5% 
Empty delta sign 3 6.3% 
Indirect signs   
Cerebral edema 5 10.6% 
Obliteration  of cistern 5 4.2% 
Ventricle size   
  a. Squashed 4 8.5% 
Tentorial enhancement 2 4.2% 
Gyral enhancement - - 
Falx enhancement - - 
 
 CT brain was normal in 10 (21%) patients. Hemorrhagic infarcts were 
most common parenchymal lesions. 17 patients (36.1%) had hemorrhagic 
infarcts. 9(19%) had non - haemorrhagic infarcts, 3(6.3%) had sub-arachnoid 
hemorrhage and 1(2%) had sub-dural hematoma. 
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 Direct signs of CVT was present in 7(14.8%) patients. Cord sign was 
present in 4 (8.5%) patients. 3 (6.3%) had empty delta sign. 
 Indirect signs were common than directs signs. 
 16 patients (27.6%) had indirect signs of CVT like cerebral edema, 
tentorial enhancement obliteration of cisterns, squashing of ventricles. 
TABLE VI : MRI FINDINGS 
 No. of Patients 
(n=47) 
Percentage 
Sinus Involvement   
Superior sagittal sinus 35 74.7% 
Inferior sagital sinus 1 2% 
Transverse sinus 16 34% 
Sigmoid sinus 17 36.1% 
Cavernous sinus 2 4.2% 
Straight sinus 6 12.7% 
Internal jugular veins 2 4.2% 
Cortical vein thrombosis 5 10.6% 
Deep cerebral vein involvement 3 6.3% 
Parenchymal lesions   
Non hemorrhagic infarct 9 19.1% 
Hemorrhagic infarct 19 36.1% 
Sub-arachnoid hemorrhage 3 6.3% 
Sub dural hematoma 1 2% 
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TABLE - VIB   
 
 No. of Patients 
(n=47) 
Percentage 
Isolated sinus 18 38.2% 
   - SSS 16  
    - Isolated cortical vein 2  
Multiple sinus 29 61.7% 
 
 MRI with MR angiogram was done in all 47 patients studied. It was 
abnormal in all the patients. 
 Superior sagittal sinus was the most frequent sinus involved in CVT. 35 
(74.7%) had partial or complete occlusion of superior sagittal sinus. It was the 
only sinus involved in 16(34%) of patients and associated with other sinus 
involvement in 19 patients. 
 Sigmoid sinus and lateral sinus was the next commonly involved sinus. 
17(36.1%) cases had sigmoid sinus thrombosis, 16(34%) had lateral sinus 
involvement. Other sinus were less frequently involved straight sinus in 
6(12.7%), cavernous sinus in 2 (4.2%). Internal jugular thrombosis was seen in 
4(8.5%), one patient had inferior sagitial sinus, 5 (10.6%) had cortical vein 
thrombosis and 3(6.3%) had deep cerebral venous involvement. 
 LP done in 3 patients with meningeal signs revealed mild elevation of 
proteins in two patients. In one patient TBM wad diagnosed. 
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TABLE - VII  PREDIPOSING / ETIOLOGY FACTOR 
IDENTIFICATION. 
 No. of Patients 
(n=47) 
Percentage 
Infectious etiology 7 14.5% 
Mastoiditis 4 8.5% 
Sinusitis 1 2% 
TBM 1 2% 
Systemic - HIV 1 2% 
Non Infectious etiology 24  
Pueperium 14 29.7% 
APLA 2 4.2% 
Protein C deficiency 1 2% 
Protein S deficiency 1 2% 
OCP use 4 8.5% 
SLE 2 4.2% 
Unidentified 16 34% 
 
 Predisposing / etiologic factors were identified in 31(66%) of patients. 
 In 16 (34%) risk factors could not be identified. 
 There were varied risk factors identified in our patients.  
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 Infections were identified as risk factors in 7(14.5%) cases. In 4(8.5%) 
mastoiditis, 1 (2%) sinusitis, 1(2%) TB meningitis, 1(2%) HIV were identified 
as risk factor. 
 Among the non - infectious causes, puerperium was the common 
predisposing factor 14(29.7%) were cases of puerperal CVT. 
 Among the non - puerperal female CVT patients 4(8.5%) were 
associated with OCP usage, 2(4.2%) were diagnosed as SLE. One of the SLE 
patient had post partum CVT and other patient had OCP use as additional risk. 
 Hereditary thrombophilic conditions were not extensively investigated 
due to financial, operational difficulties. Primary antiphospholipid antibody 
syndrome was identifical as risk factor in 2(4.2%) patients. Both were males. 
1(2%) patient had both protein C and Protein S deficiency. 
 All the patients in our study were treated with anti - coagulants, anti - 
edema measures. Anti - convulsants were exhibited in patients who presented 





TABLE VIII - OUT COME AT 4 WEEKS  
 
 No. of Patients 
(n=47) 
Percentage 
Death 2 4.2% 
Complete recovery 34 72% 
Residual deficit 11 23.4% 
 
 In our study 2 patients (4.2%) died. Both these patients had deep coma 
at presentation. At the end of 4 weeks, 34(72%) recovered completely, 
11(23.4%) had neurological sequelae in the form of residual focal deficits (10 
cases), seizures (2 patients), visual  loss  (cortical  blindness) in one patient. 
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DISCUSSION 
 The first description of CVT appeared in French Literature in 1825 by 
Ribes60 as a post mortem report. Since then many series have been published. 
However the exact incidence of CVT in still unknown. 
  Most of the initial reports were from autopsy material and it was found 
to be extremely low. Ehlers35 found only 16 SSS thrombosis cases in a series of 
12,500 autopsies, and Barnett19 reported only 39 non - infective CVT in 20 
years. Kalbag and Woolf46 indicated that CVT was the principal cause of death 
in on only 1 per 2 million (21.7 persons per year) in England and Wales 
between 1952 and 1961. By contrast Towbin72 found CVT in 9% of 182 
consecutive autopsies. At Nimhans, Bangalore, of the 1710 brains examined 75 
were of primary CVT (Nagaraja et al.,52). 
 The recent publication of large clinical series suggests that the true 
incidence in much higher than that thought from initial autopsy series 
(Krayenbuhl et al.,48 Bansal et al.,6 Ford et al.,41 Rao et al.,59). 
 It is note worthy that 50% of all strokes in women occur in relation to 
pregnancy and puerperium. Cross et al.,21 attributed majority of strokes during 
pregnancy and puerperium to arterial lesions. However, barring few exceptions, 
survey of Indian literature reveals, CVT is the commonest cause of stroke in 
puerperium. Srinivasan et al.,63 reported an incidence of 4.5 per 1000 deliveries 
out of 8000 deliveries conducted in a year at a Government Hospital, Madurai. 
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 Bousser et al.,9 reported 38 patients of angiographically proven CVT in 
8 years in a single neurology department. Cantu et al.,17 reported 113 patients 
of CVT seen in their hospital in 20 years. Daif et al.,25 had encountered 40 
patients of out over 9 years in two of Saudi Arabias' Main Hospitals. Deschiens 
et al.,32 reported that 110 patients of CVT were diagnosed between 1975 and 
1990 in their hospital (France). 
 Though our study of 47 patients does not give precise information about 
the real incidence of the disease, the fact that they were seen in 2½ years at 
Government General Hospital, Chennai, suggests that CVT is not uncommon. 
TABLE - VIII : MEAN AGE OF ONSET 
Sl.No. Authors Mean age of onset (Years) 
1. Bousser et al.,9  40.8 
2. Daif et al.,25  27.8 
3. Deschiens et al.,32 36.2 
4. Zhang et al.,75  31 
5. De Bruijn et al.,30 37 
6. Terazzi et al.,71  44.8 
7. Present study  28.5 
 
 The mean age of onset of CVT in our study is similar to studies  by  
Daif et al.,25  Zhang  et al75. However Bousser et al.,9 Deschiens et al.,32 De 
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Bruijn et al., 30 Terazzi et al.,71 found higher mean age of onset. Most of their 
cases were non puerperal.  
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 The age distribution in our study is similar to most other studies. About 
59% of the patients in our series had onset between 15 and 30 years of age. 
However 50% of cases of Bousser et al.,9 series and 30% of Deschiens et al32. 
Patients were more than 40 years of age. In our series only 8% were more than 
40 years of age. 
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TABLE X : SEX DISTRIBUTION 
 
Sl.No. Authors (No. of Patients) Males Females 
1. Bousser et al.,9 (38) 21  (55.3%) 17 (44.7%) 
2. Cantu et al.,17 (113) 13 (11.5%) 100 (88.5%) 
3. Daif et al.,25 (40) 20 (50%) 20 (50%) 
4. Deschiens et al.,32 (40) 10 (25%) 30 (75%) 
5. Zhang et al.,75 (23) 9 (39.1%) 14 (60.9%) 
6. De Bruijn et al.,30 (59) 9 (16.3%) 50 (84.7%) 
7. Terazzi et al.,71 (48) 10 (30.9%) 38 (79.1%) 
8. Present Study 24 (51%) 23 (49%) 
 
 In our study the sex distribution is almost similar 51% males, 49% 
females. This is similar to the experience in Bousser et al.,9 and Daif et al.,'s25 
series, where there were 55% and 50% males respectively. Most of other 
studies have reported an increased female incidence.  
PUERPERAL AND NON PUERPERAL CVT 
 About 14(29%) of our patients were puerperal CVT and 33 (71%) were 
non - puerperal. 
 Only 1(2.6%) of the 38 patients of Bousser et al.,9 was puerperal, while 
in Deschiens et al.,32 study only 8(20%) of patients were puerperal. Only 1 
(2.5%) of Daif et al.,25 was post partum. 4 (21.1%) of 19 patients of Zuber et 
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al.,74  related to pregnancy and puerperium. Similar to these studies, most of the 
cases in our study were non - puerperal. 
 This is in contrast to the previous Indian studies, in which majority of 
the patients were related to pregnancy and puerperium. 
 D.Nagaraja et al.,52 had found that 200 out of the 230 patients (86%) of 
CVT, seen over 8 years were puerperal in nature. 
 Puerperal CVT was reported to be responsible for 25% of maternal 
deaths in Indian and complicate 4.5% of 1000 obstetric admissions Srinivasan 
et al63. Our study differs from the experience of other authors from India. 
 Cantu and Barinagarrementeria et al.,17 study of 67 patients of CVT 
associated with pregnancy and puerperium, observed that CVT patients 
associated with pregnancy and puerperium, were younger compared to non - 
puerperal CVT, and had more acute onset of symptoms (82% Vs 54% in non - 
puerperal group). 
 In our study mean age of onset was 25.1 years in puerperal CVT and 
31.7 years for non - puerperal cases. 57% of puerperal CVT had acute mode of 
presentation and 43% had subacute onset. On the other had 9% of non - 
puerperal CVT had acute onset. Most of the patients had sub-acute onset (81%) 
and 10% had chronic onset. Our study co-relates with cantu and 
Barrinagmenteria et al.,17 experience.  
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Authors (No. of Patients) 
Acute          
(48 hrs) 
Subacute   (>48 
hrs < 1month) 
Chronic       
(>1 month) 
1. Daif et al.,25 (40) 14 (35%) 16 (40%) 10 (25%) 
2. Zhang et al.,75 (23) 4 (17%) 11 (47%) 8 (34%) 
3. Terazzi et al.,71 (48) 21 (44%) 17 (35%) 10 (21%) 
4. ISCVT38 (624) 232 (37.2%) 346 (55.5%) 45 (7.2%) 
5. Present Study (47) 11 (23.4%) 33 (70.2%) 3 (6%) 
 
 About 70% of the patients in our study had a sub-acute onset of 
presentation. 55.5% of patients of ISCVT study, 40% of Daif et al.,25 series  
had subacute onset. The mode of onset in our study in similar to most other 
studies. 
 The neurological symptoms and signs encountered in our study were 
those classically associated with CVT like, headache, seizures, alteration in 
conscious level, focal deficits, bilateral papilledema and isolated inhaeramial 
hypertension. 
 Headache - headache appears to be the most common and often the 
earliest symptom in CVT patients. 
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TABLE XIII HEADACHE IN VARIOUS SERIES 
 
Sl.No. Authors (No. of patients) Percentage 
1. Prakash and Singla57 (210) 57% 
2 Krayen Buhl48 (73) 63% 
3. Kalbag and Woolf46 (34) 29% 
4. Bousser et al.,9 (38) 74% 
5. Nagaraja52, (200) 57% 
6. Ameri A & Bousser3, (110) 75% 
7. Cantu,17 (113) 80.5% 
8. Daif et al.,25 (40) 82% 
9. Zhang, et al.,75 (23) 100% 
10. Present Study (47) 85.1% 
 
 85.1% of our cases had headache. Thus similar to other studies, 
headache in the most frequent symptom in our study also. 
SEIZURES 
 The manifestation that indicate cerebral cortical involvement are 
convulsions and paralysis. At times, seizures are the heralding symptoms and 
arouse the suspicion of the diagnosis. 
 Caroll et al.,18 found seizures in 29.8% of 181 cases and that focal 
seizures were commonest. K.Srinivasan et al.,64 found seizures in 68% of 135 
cases and generalised seizures were common. 
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 Nagaraja et al52., found generalised seizures in 35% and focal seizures in 
23% of their 200 puerperal CVT patients. 14% of their patients had status 
epilepticus. Nagaraja et al55., (1997) reported seizures in 70% of their 405 
patients of puerperal CVT (40% had generalised and 30% focal becoming 
generalised). 
 Bousser et al9., reported seizures in 29% of their 38 patients. Daif et 
al25., noted 10% of their 40 patients had seizures. Deschiens et al32., reported 
seizures in 40% of their patients. 
 In our study, 40.4% of the patients had seizures. Generalised seizures 
were the commonest type occurred in 68% of patients 10.5% had focal 
seizures, 5% focal seizures becoming generalised. 15% of our patients 
presented with status epilepticus. 
 11 out of the 14 puerperal CVT (78.5%) of the study had seizures, while 
8 out of 33 (24.2%) non puerperal had seizures. This suggests that seizures are 
more common in puerperal CVT. This is supported by higher incidence of 
seizures in puerperal CVT patients of Nagaraja et al.,52 Srinivasan  and  
Natarajan  et al64. 
 Similarly the authors who reported comparitively lower incidence of 
seizures, also had a very few puerperal CVTs in their series (Bousser et al.,9 
Desichens et al.,32 and Daif et al25. 
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 Alteration in level of consciousness (ALC) 
 About 46.8% of our patients had altered sensorium at the time of 
presentation. 4 (8.4%) patients were in coma at the time of presentation. 
TABLE XIII : (ALC IN VARIOUS SERIES) 
Sl.No. Authors (No. of patients) Percentage 
1. Srinivasan and Natarajan63, (90) 44% 
2. Bousser et al.,9 (38) 26% 
3. Nagaraja et al.,52 (200) 81% 
4. Cantu and Barinagarementeria.,55 (113) 61.2% 
5. Nagaraja et al.,75 (405) 58% 
6. Zhang et al.,75 (23) 39% 
7. Present study (48) 46.8% 
 
 Our study suggests that ALC occurs in major proportion  of our patients. 
Our incidence is similar to that of most other authors except that Bousser et 
al.,9 noted ALC in only 26% of cases. 
 The probable reasons for discrepancy in our study and Bousser et al., 9) 
may be that : 
 Seizures were less frequent in their study (29%) while we noted seizures 
in 40.4% of our patients. Seizures especially in cluster may also contribute to 
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altered sensorium and this may explain the lesser frequency of ALC in Bousser 
et al.,9 series. 
Focal deficits 
 In older series by Kalbag et al.,43  Krayenbhul et al.,46 focal deficits such 
as motor or sensory deficits, dysphasia, cranial nerve deficits occurred in 50 - 
75% of patients. Nagaraja et al.,55 reported focal deficits in 66.4% of their 405 
puerperal CVT patients. Daif et al.,25 reported focal deficits in 32% of 40 
patients and Zhang et al.,75 in 52% of 23 patients. 
 In our study 55.3% of 47 patients had focal neurological deficits (motor, 
sensory, cranial nerve deficits). 
 Hemiparesis was the common focal deficit. It was seen in 57.6% of 25 
patients with focal deficit. Among patients with focal deficits 19.2% had 
monoparesis, 15.3% had multiple cranial nerve deficits. Paraplegia, sensory 
deficits were uncommon manifestations. It becomes difficult to assess the focal 
deficits with worsening sensorium 
PAPILLEDEMA 
 Bilateral papilledema was noted in 78.7% of 47 patients. 
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TABLE - XIV : PAPILLLEDEMA IN VARIOUS SERIES 
Sl.No. Authors (No. of patients) Papilledema (Percentage) 
1. Srinivasan and Natarajan et al.,63 15% 
2 Bansal  et al.,6 35% 
3. Bousser et al.,9 45% 
4. Nagaraja et al.,55 14% 
5. Cantu et al.,17 45% 
6. Daif et al.,25 66.7% 
8. Present study  78.7% 
 
 Thus the reported incidence of papilledema in CVT ranges from 14 to 
80%. 
ISOLATED INTRACRANIAL HYPERTENSION. 
 In Ameri and Bousser et al.,3  study, 20-40% of patients presented with 
features of isolated intracranial hypertension with headache, papilledema + 
abducens palsy. 47% of the 40 patients of Daif et al.,25 presented with isolated 
ICT. 
 In our series, 27.6% of 47 patients presented with manifestations of 
isolated intracranial hypertension. 
 This reflects the need for use of neuroimaging modalities like MRI with 
MRA in patients presenting with idiopathic ICT. 
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CT SCAN FINDINGS 
 As has been discussed earlier, CT scan with and without contrast 
injection is the first neuro imaging examination to carry out when CVT in 
clinically suspected, both to rule out other conditions and try to confirm CVT. 
A wide variety of abnormalities are seen on CT. The features primary due to 
thrombosis of veins or sinuses are called direct signs and those due to 
secondary effects on  brain parenchyma are referred to as indirect sign. Though 
CT is very useful and non - invasive procedure it may be normal in 10 - 20% of 
cases (Chiras et al.,20 Rao et al.,59). 
TABLE - XV : CT SCAN FINDINGS 
Sl.  






Nagaraja      
et al.,53 (68) 
Present Study 
(47) 
1. Cord Sign 6.4% - 21.9% 8.5% 




9.7% 32% 51.6% 21.2% 
4. Hemorrhagic 
infact 
19.7% 12% 40.9% 36.1% 
5. Intracerebral 
hematoma 
3.2% - 3.1% - 
6. SAH - - - 6.3% 
7. SDH - - - 2% 
8. Tentorial 
enhancement 
9.7% 16% 16% 4.2% 
9. Small ventricles 32.3% 52% - 8.5% 
10. Normal 9.7% 20% 10.9% 21.2% 
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 Normal CT scans are reported in 10 - 20% of patients (Bousser et al.9, 
Nagaraja et al.,53 Rao et al.,59). Daif et al.,25 found 42% of 40 patients had 
normal scans, whereas in Zhang et al., series75, 41% had normal scans. In our 
study, CT scan brain was normal in 21% of the patients. 
 14.8% of patients of our 47 cases had direct evidence of CVT. 8.5% had 
cord sign, 6.3% had empty delta sign. 
 27.6% of patients had indirect evidence of CVT like cerebral edema, 
tentorial enhancement, obliteration of cistern, squashing of ventricles. 
In our study indirect signs were common than direct signs. 
 Hemorrhagic infarcts were the most common parenchymal abnormality. 
36% had hemorrhagic infarct, 19% had non - hemorrhagic infarct. Subdural 
hemorrhage and sub dural hematoma were rare abnormalities seen in 6.3% and 
2% respectively. 
 Hence though CT scans are very valuable as initial neuro - imaging 
modality in suspected case of CVT to rule out other lesion (arternal strokes, 
tumors, abscess) and in some cases making a direct diagnosis of CVT, most of 
the cases require MR imaging or angiography confirmation of the diagnosis. 
MRI FINDINGS 
 MRI with MRA was done in all 47 patients in our study. It was 
abnormal in all patients. 
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TABLE - XVI 
Sl.  
No.  








1. Superior Sagittal 
Sinus 
85% 70.3% 62% 74.7% 
2. Transverse 
Sinus 
2% 68.8% 86% 34% 
3. Sigmoid sinus 5% 13.3% 51.6% 36.1% 
4. Internal jugular 
vein 
- - 12% 8.5% 
5. Straight Sinus 5% - - 12.7% 
6. Cavernous sinus - 2% - 4.2% 
7. Vein of galen & 
Deep cerebral 
veins 
- 6% 11% 6.3% 
8. Cortical veins 5% 36% 17% 6.3% 
 
 In our study superior sagittal sinus in the most common sinus involved 
in CVT. 74% of 47 patients had partial or complete occlusion of superior 
sagittal sinus. It was the only sinus involved in 16 (34%) of patients. This 
finding in similar to most other studies. 
 Transverse and sigmoid sinus are the next more common sinus involved 
in CVT in 34.4% and 36.1% of our patients. 
 Isolated sinus involvement was seen in 18 (38%) of  the patients. 67% 
patient had multiple sinus thrombosis. Most of the isolated sinus involved was 
superior sagittal sinus. 
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 63.7% of cases of Bousser et al.,13 and 65% of patients in Daif et al.,25 
study had multiple dural signs involvement. 
PREDIPOSING / RISK FACTORS 
 In Bousser et al.,13 predisposing factors were identified in 80% of 
patients. In 75% patients of 40 patients by Daif et al.,25 prediposing factors 
were identified. 
 In our study, predisposing factors were identified in 66% of our 47 
patients. In 34% patients risk factors / etiologic factors contributing to CVT 
were not identified. 
 Infective causes were responsible for CVT in 8% of 38 patients in 
Bousser et al13. In Shell and Rathe et al.,62 study, infection was the cause of 
CVT in 16% and 17% respectively. 7% of 40 patients of Daif et al.,25 had 
infections as risk factor. 
 In our study 14% of patients had infectious etiology for their CVT. This 
finding in similar to the incidence in studies by other authors. Mastoditis, 
sinusitis, TBM, HIV  were the inefctious causes our series. Mastoditis was the 
most frequent infection.  
 Among the non - infectious etiology, CVT associated with pregnancy 
and puerperium was the most common cause 29.7% of our 47 patients were 
puerperal. 
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 Only 1(2.6%) of 38 patients by Bousser  et al.,9 was puerperal and 1 
(2.5%) of Daif et al.,25 was post partum. Indian studies by Nagaraja et al.,52 
Bansal et al.,6 had found high incidence puerperal CVT in their series. 
 8.5% of the patients in our study had history of oral contraceptive in 
take. 27.5% of Deschiens et al.,32  7.9% of Bousser et al.,9 had history of oral 
contraceptive use. De Bruijn et al.,27,29 observed an significant increased risk of 
CVT in patients on oral contraceptives. 
 4.2% of patients in our study were diagnosed as SLE (one patient had 
post partum CVT and the other had OCP use as a risk factor). 
 This observation stresses the need for extensive work up of hereditary 
thrombophilic conditions even in patients who had one obvious risk factor (like 
puerperium and OCP intake). 
 4.2% of study were diagnosed as primary antiphospholipid antibody 
syndrome and all of them were males. 
 Cantu  et al.,17 review 67 patients of puerperal and 46 cases of non - 
puerperal and found Lupus Anticoagulant in 2 (4%) of the non - puerperal 
patients. 
 Zuber et al.,76 estimated aPL in 16 of their 19 CVT patients and found 
LA in only 1 patient (5%). 
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 In Bousser et al.,9 study of 38 patients 16% of case had Behcet disease. 
25% of the 40 patients in study by Daif et al.,25  were diagnosed as Behcet's 
disease. There were no patients of Behcet's disease in our patients.One of  our 
47 patients in our study had protein C and Protein S deficiency. The 
contribution of hereditary thrombophilic conditions as a risk factor could not be 
estimated because these investigations were done only in very few patients. 
This suggest that the number of patients with hereditary thrombophilic 
conditions could be higher and reflects the necessity of these investigations in 
all patients with CVT. 
TREATMENT 
 Einhaupl et al.,36 in his study of 71 patients showed significant benefit 
with heparin even in patients with hemorrhagic infarcts. 
 Diaz et al.,33 reviewed 203 CVT patients reported between 1942 and 
1990 and compared the outcome of patients treated (149 patients) and not 
treated with heparin. 91% survived in the first group compared to 36%  in 
second group. 
 Nagaraja et al.,54 compared the effect of intravenous unfractionated 
heparin with that of placebo in 57 patients of puerperal CVT and showed non - 
significant benefit of anti-coagulant treatment as compared with placebo. 
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 In our study, all 47 patients received anticoagulation with heparin until 
the patient stabilized, even if the patient had hemorrhagic infarct, sub-
arachnoid  hemorrhage, subdural hematoma. Once stabilized, patients were 
changed to oral anti - coagulants. If no prothrombotic risk factors were 
identified, anti-coagulants were stopped after 6 months. Patients with 
predisposing thrombophilic conditions were put on long term oral anti-
coagulation. There was no deterioration in the clinical neurologic status in 
treating patients with hemorrhagic infarcts, with heparin and most of the 
patients in proved. Hence we recommend anticoagulation with heparin in all 
CVT patients in acute stage, even the presence of hemorrhagic infarct, ICH and 
SAH provided there are no other contra-indication to its use. 
TABLE XVII CASE FATALITY IN RECENT SERIES OF CVT 
Sl.No. Authors (No. of patients) Mortality (%) 
1. Einhaupl, et al.,38 (71) 14% 
2 Ameri, et al.,3 (110) 6% 
3. Barinagarrementeria et al.,17 (78) 23% 
4. Daif et al.,25 (40) 10% 
5. De Bruijn et al.,30 (59) 10% 
6. Ferro, et al.,40 (142) 6% 
7. Breteau et al.,14  (55) 4% 
8. ISCVT38  (624)  4% 
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 Pregnancy or Puerpericum  
9. Cantu et al.,17 (67) 9% 
10. Nagaraja et al.,58 (150) 17% 
11. ISCVT38 (77) 4% 
12. Present Study (47) 4.5% 
 
 Mortality rate in our study in similar compared to experience of authors 
from recent studies. 
 At the end of 4 weeks, 72% of our 47 patients recovered completely. 
23.4% had residual neurological sequelae like residual focal deficits, seizures 
and visual loss. 





et al.,36  
(n=71) 
Bousser et al.,13  
(n=135) 






Total recovery 42(59%) 101(75%) 29(72%) 36 (33%) 24 (52% ) 34 (72%) 
Minor Sequelae 13(18.5%) 16(12%) 3(3%) 19      
(28.3 %) 
3(6.5%) 
Major Sequelae 6(8.5%) 12(8%) 4(10%) 6(9%) 4(9%) 
11(23.4%) 




The short term outcome our in study was similar to other studies. 
72% had good neurologic outcome. 
Since the patients were not followed up for a long duration, we could 
not comment on the long term outcome out come of patients. But unlike arterial 





1. CVT is far more common neurologic problem than previously assumed. 
2. The mode of onset is variable and spectrum of clinical presentation is 
wide. 
3. Diagnosis of CVT requires high index of suspicion. 
4. MRI with MRA is the most sensitive neuro-imaging modality in 
diagnosis of CVT. 
5. All patients with isolated ICT should undergo MRI with MRA to rule 
out CVT. 
6. Demonstration of underlying etiology may be difficult of when the 
cause is not clinically evident. 
7. Multiple risk factors can be present in a single patient. 
8. Systematic workup for hereditary thrombophilic conditions should be 
undertaken in every patient ,even when they have one obvious 





 The study involved 47 patients of proven cases of CVT. 
 The clinical profile, neuroimaging findings, predisposing / etiologic 
factors, treatment and outcome at 4 weeks were studied. 
 Mean age of study cohorts was 28.5 years. 51% were males, 49% 
females. Most of them (70.2%) had subacute onset, 23% had acute, 6.7% 
chronic onset of symptoms. 
 29.7% were puerperal CVTs and 60.8% were non puerperal. Puerperal 
CVT had earlier mean age of onset. (25.1 years) compared to non - puerperal 
CVT (31.7 years). Also most of puerperal CVT patients (57%) had acute onset 
where as most of non - puerperal CVT patients (81.8%) had subacute onset 
symptoms. 
 Headache is the most common clinical presentation in 85% of cases. 
Other clinical features were seizures (40.4%), alteration in consiousness 
(46.8%), focal deficits (55.3%), bilateral papilledema (78.7%). (27.6%) of 
patients presented with isolated ICT.  
 Of the seizures, GTCS was  most common (68.4%). Others were focal 
(10.5%), focal with secondary generalisation (5.2%) and status epilepticus 
(15.7%). 
 CT was normal in 21% of study patients. Indirect signs (27.6%) were 
common than direct signs (14.8%). 
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 MRI with MRA was reliable as sole investigation in the diagnosis of 
CVT. (38.2%) had isolated sinus involvement (61.7%) had multiple sinus 
involvement. SSS was the most commonly involved sinus. 
 Other commonly involved sinuses are sigmoid (36.1%) and lateral sinus 
(34%). (10.6%) had cortical vein involvement deep vein system was involved 
in (6%) and cavernous sinus in 4.2% and IJV in (4.2%). 
 Predisposing / etiologic factors identified (66%) of our patients. Varied 
risk factors were identified in our patients. (14.5%) were related to infectious 
causes. Among the non infectious etiology puerperuim (29.7%) was the 
common risk factor. Others include OCP use (8.5%), SLE (4.2%), APLA 
(4.2%). 
 All our patients improved with heparin treatment despite hemorrhagic 
and SAH.  
 Mortality was (4.2%) in out study. Most of our patients had a good 
neurological outcome. (72%) had complete recovery and (23%) had residual 
sequelae like focal deficits, recurrent seizures and visual loss. 
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NAME :                                             AGE :                         SEX : 
 
OCCUPATION :   INCOME :  MRD NO  : 
 








SYMPTOMS                        PRESENT/ABSENT            DURATION 
 
 




Vomiting    : 
 
Loss of consiousness: 
 
Altered sensorium    : 
 
Convulsions  : 
 








Limb weakness          :   Right/left    Upper limbs Lower limbs 
 
 
Speech disturbances : 
 
 





Chronology  of symptoms(short history): 
 










Ear ache                    
Ear discharge             
Diarrhoea                      


























FOR  FEMALES: 
 
MENSTRUAL HISTORY 
Regularity            
LMP 
OCP intake 
Marriage :                  
Consanguinity:  
OBSTETRIC HISTORY         
 
Gravida                                   Para   
Recurrent  abortions:  




Date of delivery 
Normal vaginal delivery/ LSCS: 
Complications during labor 















EXAMINATION :                                      Present     or    Absent                              
Febrile            :                                  
Anemia          : 
Clubbing        : 
Edema            : 
Jaundice        
Cyanosis         : 
Lymphadenopathy : 
Signs of dehydration 











 Speech  
 Other Hf abnormality    (Normal/Abnormal) 
       (Present / Absent) 
 CRANIAL NERVES RIGHT LEFT NORMAL / 
ABNORMAL 
I    Olfaction    
II   Visual acuity 
      Field 
      Color vision 
   







   
V    
VII-Facial lag 
       UMN/LMN 
   
VIII    
IX    
X    
XI    
XII                      
 
SPINO MOTOR SYSTEM:    
 
               
 RIGHT LEFT NORMAL / 
ABNORMAL 
Tone               UL 
 







Power             UL 
 







Reflexes     














Deep tendon reflexes 
                      UL 
 












plantar    





                                 UL  














                   Present    or    Absent 
 
 
CEREBELLAR INVOLVEMENT      







OTHER SYSTEMS:        
 
ENT EXAMINATION  Sinusitis          : present/absent 
 
     Mastoids         : present/absent 
 
 
CVS - Normal/Abnormal 
 
 
ABNORMAL FINDINGS          
 
                         
RS                                 :   Normal / Abnormal 
 
 






INVESTIGATIONS: DONE / NOT DONE    NORMAL OR ABNORMAL 
 
1) Hemogram : 
Hb 
     TC 
     DC 
     ESR 
     Platelets 
 
2) Bl. Sugar: 
          urea  
          creatinine 
          electrolytes   
 
3) Lipid profile: 
          Total cholesterol 
          TGL 
          LDL 
 
4) BT 
    CT 
    aPTT 
















12) PROTEIN C 
 
13) PROTEIN S  
 
14) FACTOR V LEIDEN 
 





18) RHEUMATOID FACTOR 
 
19) USG ABDOMEN 
 
20)       DOPPLER LOWER LIMBS 
 
21)       OTHERS(SPECIFY) 
 
22) CT BRAIN: (with and without - contrast ) 
 
 
 Present or Absent 
Normal  
Non - hemorrhagic infarct  
Hemorrhagic infarct  
Intrancerebal hematoma  
Sub-arachnoid hemorrhage  
Sub-dural hematoma  
Direct Signs  
Cord Sign  
Empty delta sign  
Indirect signs  
Cerebral edema  
Obliteration  of cistern  
Ventricle size  
  a. Squashed  
Tentorial enhancement  
Gyral enhancement  
Falx enhancement  
23) MRI BRAIN &MRV: 
 
 Involved / Not Involved 
or   present/absent. 
Sinus Involvement  
Superior sagittal sinus  
Inferior sagital sinus  
Transverse sinus  
Sigmoid sinus  
Cavernous sinus  
Straight sinus  
Internal jugular veins  
Cortical vein thrombosis  
Deep cerebral vein involvement  
Non hemorrhagic infarct  
Hemorrhagic infarct  
Sub-arachnoid hemorrhage  
Sub dural hematoma  
 
 




       TYPE 
       DOSE 
       DURATION 
 
2) ORAL ANTICOAGULANTS                            GIVEN/NOT GIVEN 
     
        DOSE 
        DURATION 
 
 
3) ANTI EDEMA MEASURES                            GIVEN/NOT GIVEN 




         STEROIDS 
 
4) ANTICONVULSANTS                               GIVEN/NOT GIVEN 
   
         DOSE 
         DURATION 
 
PROGRESS (AT 4 WEEKS) : 
 
       COMPLETE  RECOVERY 
       RESIDUAL DEFICIT 




RISK FACTORS OF CEREBRAL  
VENOUS THROMBOSIS    
 
IDENTIFIED  / NOT IDENTIFIED : 
 
INFECTIOUS / NON INFECTIOUS : 
 





CVT    : Cerebral venous thrombosis 
CTD    : Connective tissue disorders 
DM    : Diabetes mellitus 
HT    : Hypertension 
CAD    : Coronary artery disease 
SSS    : Superior sagittal sinus 
LS    : Lateral sinus 
TS    : Transverse Sinus 
SS    : Sigmoid sinus 
STS    : Straight sinus 
IJV    : Internal jugular vein  
DVS    : Deep Venous system 
Corti.v   : Cortical vein 
CS    : Cavernous sinus 
P    : Puerperal 
NP    : Non - Puerperal 
MRI    : Magnetic Resonance Imaging 
MRA    : Magnetic resonance angiogram 
MRV    : MR Venogram 
APLA    : Antiphospholipid antibody syndrome 
SLE    : Systemic lupus Erythematosus 
ICT    : Intracranial tension 
ICP    : Intracranial pressure 
GTCS    : Generalised tonic clonic seizures 
St. Epi   : Status Epilepticus 
CT    : Computer Tomography 
HI    : Hemorrhagic infarct 
NHI    : Non - Hemorrhagic infarct 
ICH    : Intracranial hemorrhage 
SAH    : Sub-arachnoid hemorrhage 
SDH    : Sub- dural hemorrhage 
CSF    : Cerebrospinal fluid 
ESR    : Erythrocyte Sedimentation rate 
PMN    : Polymorphonuclear cell 
ALC    : Alteration in level of consiousness 
BPE    : Bilateral paplledema 
LAC    : Lupus anti-coagulant 
OCP    : Oral contraceptives 
SA    : Sub-acute 
Chr.    : Chronic 
HP    : Hemiparesis / hemiplegia 
M    : Monoparesis / monoplegia 
P.P    : Paraparesis / paraplegia 
Cr.N. Defi.   : Cranial Nerve deficitis 
Men. Irrt.   : Meningeal irritation 
C.Ede.   : Cerebral edema 
Obli. Cis.   : Obliteration of Cisterns 
Vent. Squ   : Ventricles squashed 
Tent. Enh.   : Tentorial Enhancement 
Gy / Fx. Enh.   : Gyrac or Falx enhancement 
Inf.    : Infectious etiology 
UL                                       :          Upper limb. 
LL                                        :          Lower limb 
JPS                                       :          Joint position sense 
CVS                                     :         Cardiovascular system. 
RS                                        :          Respiratory system 
DVT                                     :          Deep vein thrombosis 
PIH                                       :          Pregnancy induced hypertension 














1 18 F P - + - + + - - - + - - + - - + - - - + - -
2 26 F P + - + - - - - - + - + - - + - - + - - -
3 27 F P - + - + + - - - + - - - - - + - - - + - +
4 20 F P + - + - - - - - - - - - - - - - - + - -
5 22 F P - + - - + - - + - - - - + - + - + - + + -
6 25 F P - + - + + - - + - - - - - - + - - - + + -
7 29 F P + - + + - + - + - - + - - + - - + - - -
8 24 F P + - + + - - + - - - - - - + - - - + - +
9 24 F P + - + - - - - - - - - - - - - - - + - +
10 36 F P + - - + - - - + - - + - - + - - - + - +
11 22 F P - + - + + - - - + - - - - - + - - - + + -
12 27 F P - + - + + - - - + - + - - - - - - - + + -
13 26 F P + - + + - - - + - + - - - + - - - + + -
14 26 F P + - + + + - - - - - - - + + - - + - - -
15 35 F NP - + - + - - - - - - + - - - + - - + - - -
16 23 F NP - + - + - - - - - - - - - - - - - + - - -
17 26 F NP + - + - - - - - - - - - + + - - - + + -
18 24 F NP - + - + + - - - + - - - - - + - + + - - -
19 25 F NP - + - - - - - - - - - - - - - - - + - - -
20 21 F NP - + - + - - - - - - - - - - + - + + - - -
21 38 F NP - + - + - - - - - - + - - - + - - + - - -
22 37 F NP - + - + - - - - - - + - - - + - - + - - -
Level of 













On Set Type of Seizures Focal Deficits
Sl.
No. Age Sex P/NP














23 27 F NP - + - + + - - - + - + - - - + - - + - + -
24 22 M NP + - - + + + - - - - + - - - + - - - + - +
25 22 M NP - + - + - - - - - - + - - - + - - + - - -
26 38 M NP - + - + - - - - - - + - - - + - - - + - -
27 29 M NP - + - + - - - - - - + - - + - - - + - - -
28 48 M NP - + - + + + - - - - - - - - - - - - + - +
29 27 M NP - + - + - - - - - - + - - + - - - - + - +
30 38 M NP - - + + - - - - - - - - - - + + - + - - -
31 38 M NP - + - + - - - - - - - - - - - - - + - - -
32 32 M NP + - - + - - - - - - + - - - + - - - + - +
33 27 M NP - + - + - - - - - - - - - - + + - + - - -
34 27 M NP - - + + - - - - + - - - - - + + - + - - -
35 36 M NP - - + + + - - - - - + - - - + - - - + + -
36 55 M NP - + - + - - - - + - - - - - - - - + - - -
37 55 M NP - + - + + - - - - - - + - - + - - - + + -
38 24 M NP - + - + - - - - - - - - - - + + - + - - -
39 22 M NP - + - + - - - - - - - - - - + + - + - - -
40 25 M NP - + - + - - - - - - - - - - + + - + - - -
41 26 M NP - + - + - - - - - - - - - - + + - + - - -
42 35 M NP - + - + - - - - + - - - - - + + - + - - -
43 25 M NP - + - + + - - - - - - - - - + - - - + + -
44 33 M NP - + - + - - - - + - + - - - + - - + - - -
45 34 M NP - + - + + - - - - - + - - - + + + + - - -
46 64 M NP - + - + - - - - - - - - - - + + - + - + -










































































































1 - - + - - - - - - - - + - - - - - - - + - - + - - - - + - - - - - - + -
2 - + - SAH - - - - - - - + - + - - - - - - + SAH - + - - - + - - - - - - + -
3 - - + - - - - - - - - + - - - - - - - + - - + - - - - + - - - - - - + -
4 - - - SAH - - - - - - - - - + + - - - - - - SAH - + - - - + - - - - - - + -
5 - - + - + + - - - - - + - - + - - - - + - - - + - - - + - - - - + - - +
6 - + - - - - - - - - - + - - - - - - - - + - + - - - - + - - - - - - + -
7 - - + - - - - - - - - + - - - - - - - + - - + - - - - + - - - - - + - -
8 - - + - + - + - + - - + - - - - - - - + - - + - - - - + - - - - - - - +
9 + - - - - - - - - - - - - - + - - - - - - - + - - - - + - - - - - - + -
10 - - + - - - - - - - - + - - - - - - - + - - + - - - - + - - - - - - + -
11 - + - - - - - - - - - + - + + - - - - - + - - + - - - + - - - - - - + -
12 - - + - - - - - - - - + - - - - - - - + - - - + - - - + - - - - - - - +
13 - + - - - - - - - - - + - + - - + - - - + - - + - - - + - - - - - - - +
14 - - - - - - - - - - - + - - - - - + - - - - - + - - - + - - - - - - + -
15 - + - - - - - - - + - + - + - - - - - - + - - + - - HIV - - - - - - - + -
16 - + - - - - - - - + - - + + + - - - - - + - - + - - - - - - - - - - + -
17 - - - - - + - + + - - + - + + - + + + - - - - + - - - - - - - - - - + -
18 - - - - - - - - - - - - - - - - - - - - - - - + - - - - - - - - - - - +
19 + - - - - - - - - - - - - - - - - + - - - - + - - - - - - - - + - - + -
20 - - + - - - - - - - - + - - + - - - - + - - - + - - - - - - - + - - + -
21 - - - SDH - - - - - - - + - - + - - - - - - SDH - + - - - - - - - - - - - +
22 - + - - - - - - - - - + - - - - - - - - + - + - - - - - - - - + + - - +
23 - - - - - - - - - - - + - - + - - - - - - - - + - - - - - - - + - - + -
Sl
No.
CT Findings MRI Findings Risk Factors Identification Outcome









































25 - - + - - - - - - - - + - - - - - - - + - - + - - - - - - - - - - - - +
26 - - - - + + - - - - - + - - + + - + - - - - - + - - + - - - - - - - + -
27 - - + - - - - - - - - - - - - - - - - + - - - + - - - - - - - - - - + -
28 - - + - - - - - - - - - - - - - - - - + - - - + - - - - - - - - - - + -
29 - - + - - - - - - - - + - - - - - - - + - - + - - - - - - - - - - - + -
30 + - - - - - - - - - - - - - - + - - - - - - - + - - - - - - - - - - + -
31 + - - - - - - - - - - + - + - - - + - - - - - + - - + - - - - - - - + -
32 - - + - - - - - - - - + - - - - - - - + - - + - - - - - - - - - - - - +
33 - - - - - - + + + - - + - + + + - - - - - - - + - - - - - - - - - - + -
34 + - - - - - - - - - - + - - - - - - - - - - + - - - + - - - - - - - + -
35 - - + - - - - - - - - + - - + - - - - + - - - + - - - - - - - - - - + -
36 - - - - - - - - - - - + - + + - - - - - - - - + - - - - - - - - - - + -
37 - - + - - - - - - - - - - - - - - - - + - - - + - - - - - - - - - - + -
38 + - - - - - - - - - - - - + + + - - - - - - - + - - - - - - - - - - + -
39 + - - - - - - - - - - - - + - + - - - - - - - + - - - - - - - - - - + -
40 + - - - - - - - - - - + - + + - - - - - - - - + - - - - - - - - - - + -
41 + - - - - - - - - - - + - - - - - - - - - - + - - - - - - - - - - - + -
42 + - - - - - - - - - - + - + + - - - - - - - - + - - - - - - - - - + - -
43 - - - - - - + + + - - + - - - - - - - - - - + - - - - - - - - - - - + -
44 - + - - - - + + - - - + - - - - - - - - + - + - - - - - - - - - - - + -
45 - - - - - - + + - - - - - + + + - - - + - - - + - - - - - - - - - - - +
46 - - - - - - - - - - - + - + - - - - + - - - - + - - + - - - - - - - + -
Risk Factors Identification Outcome
Sl
No.
CT Findings MRI Findings























CT Brain plain of a study patient showing the "cord sign" and  




















MRI Brain of  a CVT  Patient T1W image showing bilateral 















































MRV of a CVT patient showing absence of flow void in the left 















































MRI brain T1W image showing SSS thrombosed and associated 
cortical vein thrombosis 
